PRESS RELEASES

Date Title and Summary View
Toggle Summary PRO-PHARMACEUTICALS UPDATES RIGHTS OFFERING: FILES AMENDED REGISTRATION STATEMENT View HTML
Toggle Summary PRO-PHARMACEUTICALS NAMES THEODORE D. ZUCCONI, PH.D., CHIEF EXECUTIVE OFFICER
Gil Amelio, Ph.D., Jim Czirr, Rod Martin, J.D., Peter Traber, M.D., Named to the Company's Board of Directors
View HTML
Toggle Summary PRO-PHARMACEUTICALS CLOSES INITIAL $1.8 MILLION TRANCHE OF UP TO $6.0 MILLION PRIVATE PLACEMENT View HTML
Toggle Summary PRO-PHARMACEUTICALS POSTPONES RIGHTS OFFERING View HTML
Toggle Summary PRO-PHARMACEUTICALS LICENSES TO PROCAPS S.A. EXCLUSIVE MARKETING and DISTRIBUTION RIGHTS to COMMERCIALIZE DAVANAT® to TREAT CANCER in COLOMBIA, SOUTH AMERICA View HTML
Toggle Summary Pro-Pharmaceuticals' DAVANAT® Prevents Mucositis, a Serious Side Effect of Chemotherapy, in All 100 Cancer Patients Treated View HTML
Toggle Summary PRO-PHARMACEUTICALS ENGAGES PERCEPTIVE IMAGINEERING TO MARKET DAVANAT® IN CENTRAL & SOUTH AMERICA View HTML
Toggle Summary Pro-Pharmaceuticals Reports First Quarter 2009 Financial Results View HTML
Toggle Summary PRO-PHARMACEUTICALS REPORTS FULL YEAR and FOURTH QUARTER 2008 FINANCIAL RESULTS View HTML
Toggle Summary PRO-PHARMACEUTICALS' CHIEF SCIENTIST PUBLISHED ARTICLES IN THREE PRESTIGIOUS PEER-REVIEWED JOURNALS
NMR Studies Further Define DAVANAT®'s Mechanism of Action with Galectin Receptors Found on Solid Tumors
View HTML